Page last updated: 2024-11-04

thiorphan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thiorphan is a potent and selective inhibitor of the enzyme aminopeptidase N (APN), also known as CD13. It is a synthetic compound, originally developed as a potential drug for the treatment of Alzheimer's disease, but has since been studied for its various pharmacological effects. Thiorphan is a small molecule with a molecular weight of 240.3 g/mol. It is readily absorbed after oral administration and has a relatively short half-life. The compound is known to cross the blood-brain barrier, making it suitable for the treatment of neurological conditions. In addition to inhibiting APN, thiorphan has been shown to have other effects, including: inhibiting the release of neuropeptides, reducing inflammation, and promoting neuroprotection. Due to its multiple pharmacological activities, thiorphan has been investigated for its potential therapeutic benefits in a variety of conditions, such as: Alzheimer's disease, Parkinson's disease, stroke, and cancer. Current research focuses on exploring its applications in various therapeutic areas, including its potential role in regulating immune responses and its effectiveness in treating specific types of cancers.'

Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3132
CHEMBL ID10247
CHEBI ID9568
SCHEMBL ID401174
MeSH IDM0023434
PubMed CID4369380
CHEMBL ID298827
SCHEMBL ID49662
MeSH IDM0023434

Synonyms (113)

Synonym
smr001233267
MLS002153923
BRD-A56012032-001-06-4
EU-0101139
dl-thiorphan, >=98% (tlc)
PRESTWICK_694
BIO2_000263
BIO2_000743
BSPBIO_000626
LOPAC0_001139
PRESTWICK3_000633
BPBIO1_000690
PRESTWICK2_000633
SMP2_000064
2-(2-benzyl-3-sulfanylpropanamido)acetic acid
chembl10247 ,
bdbm21641
76721-89-6
C01619
thiorphan
IDI1_034013
dl-thiorphan
NCGC00094405-03
glycine, n-(2-(mercaptomethyl)-1-oxo-3-phenylpropyl)-, (+-)-
KBIOSS_000263
KBIO3_000525
KBIO2_005399
KBIO2_002831
KBIO3_000526
KBIOGR_000263
KBIO2_000263
SPBIO_002845
PRESTWICK1_000633
PRESTWICK0_000633
BSPBIO_001543
nsc727676
nsc-727676
NCGC00094405-04
NCGC00094405-01
NCGC00094405-02
NCGC00016033-02
HMS1989N05
dl-3-mercapto-2-benzylpropanoylglycine
T 6031
NCGC00016033-06
chebi:9568 ,
HMS1791N05
HMS1361N05
HMS1569P08
2-[(2-benzyl-3-sulfanylpropanoyl)amino]acetic acid
n-(2-benzyl-3-sulfanylpropanoyl)glycine
HMS2096P08
HMS3263D19
unii-b79l7b5x3z
nsc 727676
b79l7b5x3z ,
CCG-205213
HMS2230G03
NCGC00016033-03
NCGC00016033-04
NCGC00016033-05
FT-0675192
LP01139
(+/-)-thiorphan
(((2rs)-2-benzyl-3-sulfanylpropanoyl)amino)acetic acid
n-((rs)-2-benzyl-3-mercaptopropanoyl)-glycine
glycine, n-(2-(mercaptomethyl)-1-oxo-3-phenylpropyl)-
racecadotril impurity b [ep impurity]
HMS3373F16
tox21_501139
NCGC00261824-01
AKOS024257670
SCHEMBL401174
FD21637
2-[(2-benzyl-3-sulfanyl-propanoyl)amino]acetic acid
HMS3402N05
mfcd00058435
(+/-)-n-(3-mercapto-2-benzylpropionyl)glycine
sr-01000076164
SR-01000076164-1
SR-01000076164-5
(dl-3-mercapto-2-benzylpropanoyl)-gly-oh
HMS3713P08
2-(2-benzyl-3-mercaptopropanamido)acetic acid
dl-thiorphan - cas 76721-89-6
Q7784695
DTXSID70868412
SDCCGSBI-0051106.P003
NCGC00016033-11
thiorphan (dl)
AS-79321
HY-W013375
CS-W014091
n-alpha-(dl-3-mercapto-2-benzylpropanoyl)-glycine
neprilysin/neutral endopeptidase inhibitor
lopac-t-6031
NCGC00016033-01
NCGC00016933-01
cas-76721-89-6
1ZDP ,
(2-mercaptomethyl-3-phenyl-propionyl)-glycine
DB08626
(s)-thiorphan
CHEMBL298827 ,
2-[1-(2-carboxy-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethylamino]-4-phenyl-butyric acid(thiorphan)
bdbm50024102
((s)-2-mercaptomethyl-3-phenyl-propionylamino)-acetic acid
(s) (2-mercaptomethyl-3-phenyl-propionylamino)-acetic acid
2-[[(2s)-2-benzyl-3-sulfanylpropanoyl]amino]acetic acid
2-[(2s)-2-benzyl-3-sulfanylpropanamido]acetic acid
gtpl5278
SCHEMBL49662
n-[(2s)-2-benzyl-3-sulfanylpropanoyl]glycine

Research Excerpts

Effects

ExcerptReferenceRelevance
"Azidothiorphan has also been found to produce a long-lasting naloxone-reversible analgesia after intracerebroventricular administration."( Irreversible photolabeling of active site of neutral endopeptidase-24.11 "enkephalinase" by azidothiorphan and [14C]-azidothiorphan.
Beaumont, A; Chaillet, P; Crine, P; Hernandez, JF; Roques, BP, 1987
)
0.95

Treatment

The treatment with thiorphan at concentrations of 0.4-1.6 mg/ml inhibited growth of cultured in vitro B16 melanoma cell in comparison with control culture. Treatment with thorphan at a dose 25 micrograms augmented cytotoxic activity of natural killer (NK) cells and macrophages.

ExcerptReferenceRelevance
"The treatment with thiorphan at concentrations of 0.4-1.6 mg/ml inhibited growth of cultured in vitro B16 melanoma cell in comparison with control culture."( Antitumor activity of bestatin and thiorphan in mice.
Belowski, D; Herman, ZS; Kowalski, J; Madej, A, 1995
)
0.89
"Treatment with thiorphan at a dose 25 micrograms augmented cytotoxic activity of natural killer (NK) cells and macrophages."( Effects of thiorphan, bestatin and captopril on the Lewis lung carcinoma metastases in mice.
Belowski, D; Herman, ZS; Kowalski, J; Madej, A,
)
0.86
"A pretreatment with thiorphan, an inhibitor of neutral endopeptidases, significantly reduced such a difference."( Transglutaminase-synthesized spermine derivative of substance P recognizes rat portal vein neurokinin-3 receptors.
Costa, C; Cozzolino, A; Esposito, C; Falciani, M; Filippelli, A; Porta, R; Rossi, F, 1997
)
0.61
"Pretreatment with thiorphan potentiated the increases of RAR activity and RL induced by SP but had no effect on the RAR and RL responses to NKA and NKB."( Effects of tachykinins on rapidly adapting pulmonary stretch receptors and total lung resistance in anesthetized, artificially ventilated rabbits.
Matsumoto, S; Ojima, K; Saiki, C; Takahashi, T; Takeda, M, 1997
)
0.62
"Treatment with thiorphan (10 mg/kg i.v."( Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters.
Blaine, EB; McGraw, DE; Smits, GJ; Trapani, AJ, 1990
)
0.62

Toxicity

ExcerptReferenceRelevance
" Apart from the acute toxic effect of the peptide, the distribution in different organs was also investigated."( Inhalation of substance P and thiorphan: acute toxicity and effects on respiration in conscious guinea pigs.
Edvinsson, AA; Koch, BL; Koskinen, LO,
)
0.42
"No increases in deaths, serious adverse events, or dropouts from adverse events were observed for the ecadotril group compared with placebo."( A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study.
Burnett, JC; Cody, RJ; Elkayam, U; Gattis, WA; Gheorghiade, M; Gilbert, J; Goldstein, S; Granger, CB; Kasper, EK; Katz, SD; Massie, BM; McKenney, JM; Messineo, FC; O'Connor, CM, 1999
)
0.3
"In this small pilot study, ecadotril in doses of 50 to 400 mg twice daily was generally well-tolerated and without severe short-term adverse effects in patients with mild to moderate heart failure."( A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study.
Burnett, JC; Cody, RJ; Elkayam, U; Gattis, WA; Gheorghiade, M; Gilbert, J; Goldstein, S; Granger, CB; Kasper, EK; Katz, SD; Massie, BM; McKenney, JM; Messineo, FC; O'Connor, CM, 1999
)
0.3
" There was no evidence of an effect accumulated over time, and reversibility of toxic effects was evident."( Acute, subchronic, and chronic toxicity of ecadotril in dogs.
Goetze, L; Maertins, T; von Keutz, E, 2000
)
0.31
" The no-observable adverse effect level of ecadotril following daily oral administration was 100 mg/kg/d; repeated administration of 300 mg/kg/d revealed the hematopoietic system as the primary toxicologic target."( Acute, subchronic, and chronic toxicity of ecadotril in dogs.
Goetze, L; Maertins, T; von Keutz, E, 2000
)
0.31

Dosage Studied

Leucine-thiorphan shifted, in concentration-dependent fashions, the dose-response curves to all tachykinins to lower concentrations. Inhibition of neutral endopeptidase activity by phosphoramidon or thiorphan potentiated the effect of ANF. Thiorphan (1 mg/kg) stimulated gastric emptying and inhibited it at higher dosage.

ExcerptRelevanceReference
" The dose-response curves for NKA and SP were shifted to small degrees (less than 3-fold) to the right by atropine and to the left by indomethacin."( Tachykinin-induced dyspnea in conscious guinea pigs.
Buckner, CK; DeHaas, CJ; Krell, RD; Kusner, EJ; Lengel, DJ; Marks, RL, 1992
)
0.28
" bolus dosing with 125I-labelled ANF 99-126."( Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.
Chiu, PJ; Sybertz, EJ; Vemulapalli, S; Watkins, RW, 1991
)
0.28
" A maximally effective dose of LY53857 (1 mg/kg) produced larger shifts of the dose-response curves to serotonin, 5-methoxytryptamine and alpha-methyl-serotonin than did a maximally effective dose of ketanserin (1 mg/kg)."( A pharmacologic examination of receptors mediating serotonin-induced bronchoconstriction in the anesthetized guinea pig.
Buckner, CK; Dea, D; Krell, RD; Liberati, N, 1991
)
0.28
" In nine healthy human volunteers who had received a low oral dosage of sinorphan or retorphan in a double-blind, placebo-controlled, randomized trial, sinorphan was also 2-3 fold more potent than retorphan in inhibiting plasma enkephalinase activity."( Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans.
Ardaillou, R; Baumer, P; Chaignon, B; Cournot, A; Duchier, J; Dussaule, JC; Gros, C; Lecomte, JM; Lim, C; Souque, A, 1990
)
0.28
" Leu-thiorphan shifted the dose-response curve to SP to lower concentrations."( Enkephalinase inhibitor potentiates substance P- and electrically induced contraction in ferret trachea.
Borson, DB; Nadel, JA; Sekizawa, K; Tamaoki, J, 1987
)
0.79
" Leucine-thiorphan shifted, in concentration-dependent fashions, the dose-response curves to all tachykinins to lower concentrations."( Enkephalinase inhibitor potentiates mammalian tachykinin-induced contraction in ferret trachea.
Basbaum, CB; Borson, DB; Graf, PD; Nadel, JA; Sekizawa, K; Tamaoki, J, 1987
)
0.69
" To determine which enzymes were responsible for generating these initial metabolites, animals were first dosed with various protease inhibitors before the infusion of [14C]ANP(103-126)."( In vivo metabolism of atrial natriuretic peptide: identification of plasma metabolites and enzymes responsible for their generation.
Durley, RC; Krieter, PA; Olins, GM; Verrett, SP, 1989
)
0.28
" Similarly, chronic dosing with acetorphan after withdrawal produced no significant effect on body weight."( Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.
Livingston, SJ; Rooney, KF; Sewell, RD; Smith, HJ, 1988
)
0.27
" Administered prior to a non-fat meal, thiorphan (1 mg/kg) stimulated gastric emptying and inhibited it at higher dosage (10 mg/kg)."( Influence of enkephalinase inhibitors on gastric emptying in mice depends on the nature of the meal.
Buéno, L; Liberge, M; Rivière, PM, 1988
)
0.54
" No differences in ELGV dose-response curves to LTD4 were seen in A23187- and vehicle-exposed animals."( Inhaled A23187 produces a preferential sensitization to substance P.
Bendele, AM; Cockerham, SL; Silbaugh, SA; Stengel, PW, 1993
)
0.29
" Thiorphan caused a leftward shift of the dose-response curve to MBS."( Neutral endopeptidase inhibitor thiorphan increases airway narrowing to inhaled sodium metabisulfite in normal subjects.
Bellofiore, S; Caltagirone, F; Ciancio, N; Di Maria, GU; Mistretta, A; Pennisi, A, 1994
)
1.48
" Airway hyperresponsiveness was evidenced by significant shifts to the left of dose-response curves for intravenous acetylcholine (ACh) without a change in maximum responses to ACh."( The tachykinin NK2 receptor antagonist SR 48968 inhibits citric acid-induced airway hyperresponsiveness in guinea pigs.
Advenier, C; Emonds-Alt, X; Girard, V; Yavo, JC, 1996
)
0.29
" The dose and dosing intervals of TH were derived from previous pharmacokinetic and dose-finding studies."( The effect of inhaled thiorphan on allergen-induced airway responses in asthmatic subjects.
Bakker, PF; Diamant, Z; Kuijpers, EA; Sterk, PJ; Van der Veen, H, 1996
)
0.61
"), shifted the dose-response relationships to the right for each of the antidepressant agents (dothiepin, amitriptyline, sibutramine, (+)-oxaprotiline and paroxetine)."( The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Gray, AM; Sewell, RD; Spencer, PS, 1998
)
0.3
" The dose-response curve for ET-1 was shifted to the left in the diabetics, so that at some lower doses of ET-1 the vasoconstriction was greater than in the controls."( Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction.
Kamata, K; Kobayashi, T; Matsumoto, T; Ozawa, Y; Taguchi, K, 2010
)
0.36
" The proposed methods were successfully applied for determination of Racecadotril in its pharmaceutical dosage form."( Spectrophotometric and spectrofluorimetric methods for determination of Racecadotril.
Ali, NW; Elghobashy, MR; Mahmoud, MG; Mohammed, MA, 2011
)
0.37
" Attention should be payed to correct dosing and some well-known contra-indications."( [The treatment of acute diarrhea].
Leemans, L, 2013
)
0.39
" Thus, optimal neprilysin inhibitor dosing reveals additional cardioprotective effects on top of AT1 receptor blockade in renin-dependent hypertension."( Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
Batenburg, WW; Bhaggoe, UM; Clahsen-van Groningen, MC; de Vries, R; Domenig, O; Friesema, EC; Garrelds, IM; Hoorn, EJ; Jan Danser, AH; Leijten, FP; Poglitsch, M; Roksnoer, LC; van Veghel, R, 2015
)
0.42
" These results suggest that newer clinical-stage NEP inhibitors originally developed for other indications may be directly repositioned for treatment of acute secretory diarrhea and offer advantages over racecadotril, such as less frequent dosing and potentially improved efficacy."( Pharmacologic Comparison of Clinical Neutral Endopeptidase Inhibitors in a Rat Model of Acute Secretory Diarrhea.
Arnett, SD; Bond, BR; Campbell, MA; Choy, RK; de Hostos, E; Griggs, DW; Ji, Y; Meyers, MJ; Neckermann, G; Oliva, J; Prinsen, MJ; Ruminski, PG; Tajfirouz, D; Yu, Y, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00280.003245.467312,589.2998AID2517
phosphopantetheinyl transferaseBacillus subtilisPotency0.79430.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency13.71320.004110.890331.5287AID504466; AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency50.11876.309627.099079.4328AID602179
arylsulfatase AHomo sapiens (human)Potency21.33131.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency37.68580.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency2.81840.540617.639296.1227AID2364; AID2528
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency10.32250.00419.984825.9290AID504444
M-phase phosphoprotein 8Homo sapiens (human)Potency7.07950.177824.735279.4328AID488949
Chain A, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID886
phosphopantetheinyl transferaseBacillus subtilisPotency35.48130.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.84890.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency7.94330.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency15.84890.039816.784239.8107AID1454
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency12.58930.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency11.22020.00106.000935.4813AID944
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ThermolysinBacillus thermoproteolyticusIC50 (µMol)9.50000.00301.93259.5000AID213077
ThermolysinBacillus thermoproteolyticusKi1.80980.01151.14192.2909AID213070; AID213088
NeprilysinRattus norvegicus (Norway rat)IC50 (µMol)0.00580.00100.17022.3000AID143636; AID147352; AID147354; AID147367; AID147371; AID147372; AID1799660; AID67348; AID67355
NeprilysinRattus norvegicus (Norway rat)Ki0.04000.00170.01520.0400AID67359
NeprilysinOryctolagus cuniculus (rabbit)IC50 (µMol)0.00850.00040.66118.2000AID143520; AID147212; AID147213; AID67345
NeprilysinOryctolagus cuniculus (rabbit)Ki2.52700.00190.00300.0040AID147226; AID1798102
NeprilysinHomo sapiens (human)IC50 (µMol)0.00240.00020.54226.7000AID1127282; AID147391; AID1515581
EEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)Ki100.00000.00120.09810.1950AID1799789
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)0.22810.00010.533610.0000AID38849; AID39770
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)0.42000.00001.612910.0000AID37934
NeprilysinSus scrofa (pig)IC50 (µMol)0.00620.00620.00620.0062AID433786
Type-1 angiotensin II receptorHomo sapiens (human)Ki10.00000.00020.18374.7000AID1515578
Endothelin-converting enzyme 1Homo sapiens (human)IC50 (µMol)100.00000.01200.56782.0000AID228593
Endothelin-converting enzyme 1Homo sapiens (human)Ki5.02600.00200.00300.0040AID1798102; AID67205
Angiotensin-converting enzymeRattus norvegicus (Norway rat)Ki2.55100.00011.96427.3000AID1798102; AID38253
Squalene synthaseRattus norvegicus (Norway rat)Ki10.00000.00500.65582.6000AID1515578
Chain E, ThermolysinBacillus thermoproteolyticusKi1.80001.80001.80001.8000AID977610
Chain E, ThermolysinBacillus thermoproteolyticusKi1.80001.80001.80001.8000AID977610
Thiamine transporter 1Homo sapiens (human)Ki1.80001.80001.80001.8000AID213073
ThermolysinBacillus thermoproteolyticusIC50 (µMol)1.80000.00301.93259.5000AID213071
ThermolysinBacillus thermoproteolyticusKi1.80000.01151.14192.2909AID213073
NeprilysinRattus norvegicus (Norway rat)IC50 (µMol)0.00400.00100.17022.3000AID67819
NeprilysinOryctolagus cuniculus (rabbit)IC50 (µMol)0.00190.00040.66118.2000AID147220
NeprilysinOryctolagus cuniculus (rabbit)Ki0.00190.00190.00300.0040AID147228
NeprilysinHomo sapiens (human)IC50 (µMol)0.02000.00020.54226.7000AID1607331
NeprilysinHomo sapiens (human)Ki0.00350.00150.00440.0090AID1224570; AID1252360
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)3.73330.00010.533610.0000AID1607332; AID39767; AID9849
Aminopeptidase NHomo sapiens (human)Ki10.00000.00081.956910.0000AID1252361
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (121)

Processvia Protein(s)Taxonomy
kidney developmentNeprilysinHomo sapiens (human)
placenta developmentNeprilysinHomo sapiens (human)
proteolysisNeprilysinHomo sapiens (human)
peptide metabolic processNeprilysinHomo sapiens (human)
learning or memoryNeprilysinHomo sapiens (human)
substance P catabolic processNeprilysinHomo sapiens (human)
bradykinin catabolic processNeprilysinHomo sapiens (human)
sensory perception of painNeprilysinHomo sapiens (human)
protein catabolic processNeprilysinHomo sapiens (human)
lung developmentNeprilysinHomo sapiens (human)
hormone catabolic processNeprilysinHomo sapiens (human)
response to estrogenNeprilysinHomo sapiens (human)
creatinine metabolic processNeprilysinHomo sapiens (human)
amyloid-beta metabolic processNeprilysinHomo sapiens (human)
positive regulation of neurogenesisNeprilysinHomo sapiens (human)
neuropeptide processingNeprilysinHomo sapiens (human)
cellular response to cytokine stimulusNeprilysinHomo sapiens (human)
cellular response to UV-ANeprilysinHomo sapiens (human)
cellular response to UV-BNeprilysinHomo sapiens (human)
replicative senescenceNeprilysinHomo sapiens (human)
amyloid-beta clearanceNeprilysinHomo sapiens (human)
amyloid-beta clearance by cellular catabolic processNeprilysinHomo sapiens (human)
positive regulation of long-term synaptic potentiationNeprilysinHomo sapiens (human)
protein processingNeprilysinHomo sapiens (human)
brain developmentEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
heart developmentEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
cardioblast differentiationEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
methylationEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
protein processingEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
regulation of cell growthType-1 angiotensin II receptorHomo sapiens (human)
kidney developmentType-1 angiotensin II receptorHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionType-1 angiotensin II receptorHomo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationType-1 angiotensin II receptorHomo sapiens (human)
Rho protein signal transductionType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationType-1 angiotensin II receptorHomo sapiens (human)
regulation of vasoconstrictionType-1 angiotensin II receptorHomo sapiens (human)
calcium-mediated signalingType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityType-1 angiotensin II receptorHomo sapiens (human)
low-density lipoprotein particle remodelingType-1 angiotensin II receptorHomo sapiens (human)
regulation of renal sodium excretionType-1 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
regulation of cell population proliferationType-1 angiotensin II receptorHomo sapiens (human)
symbiont entry into host cellType-1 angiotensin II receptorHomo sapiens (human)
regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of protein metabolic processType-1 angiotensin II receptorHomo sapiens (human)
cell chemotaxisType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
blood vessel diameter maintenanceType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesisType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of CoA-transferase activityType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processType-1 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of receptor recyclingEndothelin-converting enzyme 1Homo sapiens (human)
regulation of systemic arterial blood pressure by endothelinEndothelin-converting enzyme 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayEndothelin-converting enzyme 1Homo sapiens (human)
heart developmentEndothelin-converting enzyme 1Homo sapiens (human)
substance P catabolic processEndothelin-converting enzyme 1Homo sapiens (human)
bradykinin catabolic processEndothelin-converting enzyme 1Homo sapiens (human)
calcitonin catabolic processEndothelin-converting enzyme 1Homo sapiens (human)
protein processingEndothelin-converting enzyme 1Homo sapiens (human)
peptide hormone processingEndothelin-converting enzyme 1Homo sapiens (human)
regulation of vasoconstrictionEndothelin-converting enzyme 1Homo sapiens (human)
endothelin maturationEndothelin-converting enzyme 1Homo sapiens (human)
embryonic heart tube developmentEndothelin-converting enzyme 1Homo sapiens (human)
hormone catabolic processEndothelin-converting enzyme 1Homo sapiens (human)
embryonic digit morphogenesisEndothelin-converting enzyme 1Homo sapiens (human)
ear developmentEndothelin-converting enzyme 1Homo sapiens (human)
pharyngeal system developmentEndothelin-converting enzyme 1Homo sapiens (human)
axonogenesis involved in innervationEndothelin-converting enzyme 1Homo sapiens (human)
sympathetic neuron axon guidanceEndothelin-converting enzyme 1Homo sapiens (human)
semaphorin-plexin signaling pathway involved in axon guidanceEndothelin-converting enzyme 1Homo sapiens (human)
spermatogenesisThiamine transporter 1Homo sapiens (human)
thiamine diphosphate biosynthetic processThiamine transporter 1Homo sapiens (human)
folic acid transportThiamine transporter 1Homo sapiens (human)
thiamine transportThiamine transporter 1Homo sapiens (human)
pyridoxine transportThiamine transporter 1Homo sapiens (human)
thiamine-containing compound metabolic processThiamine transporter 1Homo sapiens (human)
thiamine transmembrane transportThiamine transporter 1Homo sapiens (human)
transmembrane transportThiamine transporter 1Homo sapiens (human)
kidney developmentNeprilysinHomo sapiens (human)
placenta developmentNeprilysinHomo sapiens (human)
proteolysisNeprilysinHomo sapiens (human)
peptide metabolic processNeprilysinHomo sapiens (human)
learning or memoryNeprilysinHomo sapiens (human)
substance P catabolic processNeprilysinHomo sapiens (human)
bradykinin catabolic processNeprilysinHomo sapiens (human)
sensory perception of painNeprilysinHomo sapiens (human)
protein catabolic processNeprilysinHomo sapiens (human)
lung developmentNeprilysinHomo sapiens (human)
hormone catabolic processNeprilysinHomo sapiens (human)
response to estrogenNeprilysinHomo sapiens (human)
creatinine metabolic processNeprilysinHomo sapiens (human)
amyloid-beta metabolic processNeprilysinHomo sapiens (human)
positive regulation of neurogenesisNeprilysinHomo sapiens (human)
neuropeptide processingNeprilysinHomo sapiens (human)
cellular response to cytokine stimulusNeprilysinHomo sapiens (human)
cellular response to UV-ANeprilysinHomo sapiens (human)
cellular response to UV-BNeprilysinHomo sapiens (human)
replicative senescenceNeprilysinHomo sapiens (human)
amyloid-beta clearanceNeprilysinHomo sapiens (human)
amyloid-beta clearance by cellular catabolic processNeprilysinHomo sapiens (human)
positive regulation of long-term synaptic potentiationNeprilysinHomo sapiens (human)
protein processingNeprilysinHomo sapiens (human)
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
angiogenesisAminopeptidase NHomo sapiens (human)
cell differentiationAminopeptidase NHomo sapiens (human)
symbiont entry into host cellAminopeptidase NHomo sapiens (human)
proteolysisAminopeptidase NHomo sapiens (human)
peptide catabolic processAminopeptidase NHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
phosphatidylserine bindingNeprilysinHomo sapiens (human)
endopeptidase activityNeprilysinHomo sapiens (human)
metalloendopeptidase activityNeprilysinHomo sapiens (human)
protein bindingNeprilysinHomo sapiens (human)
exopeptidase activityNeprilysinHomo sapiens (human)
zinc ion bindingNeprilysinHomo sapiens (human)
peptide bindingNeprilysinHomo sapiens (human)
protein homodimerization activityNeprilysinHomo sapiens (human)
oligopeptidase activityNeprilysinHomo sapiens (human)
cardiolipin bindingNeprilysinHomo sapiens (human)
methyltransferase activityEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
metal ion bindingEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
metalloendopeptidase activityEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin type I receptor activityType-1 angiotensin II receptorHomo sapiens (human)
angiotensin type II receptor activityType-1 angiotensin II receptorHomo sapiens (human)
protein bindingType-1 angiotensin II receptorHomo sapiens (human)
bradykinin receptor bindingType-1 angiotensin II receptorHomo sapiens (human)
protein heterodimerization activityType-1 angiotensin II receptorHomo sapiens (human)
endopeptidase activityEndothelin-converting enzyme 1Homo sapiens (human)
metalloendopeptidase activityEndothelin-converting enzyme 1Homo sapiens (human)
protein bindingEndothelin-converting enzyme 1Homo sapiens (human)
zinc ion bindingEndothelin-converting enzyme 1Homo sapiens (human)
peptide hormone bindingEndothelin-converting enzyme 1Homo sapiens (human)
protein homodimerization activityEndothelin-converting enzyme 1Homo sapiens (human)
protein bindingThiamine transporter 1Homo sapiens (human)
folic acid transmembrane transporter activityThiamine transporter 1Homo sapiens (human)
thiamine transmembrane transporter activityThiamine transporter 1Homo sapiens (human)
phosphatidylserine bindingNeprilysinHomo sapiens (human)
endopeptidase activityNeprilysinHomo sapiens (human)
metalloendopeptidase activityNeprilysinHomo sapiens (human)
protein bindingNeprilysinHomo sapiens (human)
exopeptidase activityNeprilysinHomo sapiens (human)
zinc ion bindingNeprilysinHomo sapiens (human)
peptide bindingNeprilysinHomo sapiens (human)
protein homodimerization activityNeprilysinHomo sapiens (human)
oligopeptidase activityNeprilysinHomo sapiens (human)
cardiolipin bindingNeprilysinHomo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
virus receptor activityAminopeptidase NHomo sapiens (human)
aminopeptidase activityAminopeptidase NHomo sapiens (human)
metallopeptidase activityAminopeptidase NHomo sapiens (human)
signaling receptor activityAminopeptidase NHomo sapiens (human)
metalloaminopeptidase activityAminopeptidase NHomo sapiens (human)
zinc ion bindingAminopeptidase NHomo sapiens (human)
peptide bindingAminopeptidase NHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
cytoplasmNeprilysinHomo sapiens (human)
early endosomeNeprilysinHomo sapiens (human)
trans-Golgi networkNeprilysinHomo sapiens (human)
plasma membraneNeprilysinHomo sapiens (human)
brush borderNeprilysinHomo sapiens (human)
focal adhesionNeprilysinHomo sapiens (human)
synaptic vesicleNeprilysinHomo sapiens (human)
cell surfaceNeprilysinHomo sapiens (human)
membraneNeprilysinHomo sapiens (human)
axonNeprilysinHomo sapiens (human)
dendriteNeprilysinHomo sapiens (human)
secretory granule membraneNeprilysinHomo sapiens (human)
cytoplasmic vesicleNeprilysinHomo sapiens (human)
neuronal cell bodyNeprilysinHomo sapiens (human)
neuron projection terminusNeprilysinHomo sapiens (human)
membrane raftNeprilysinHomo sapiens (human)
synapseNeprilysinHomo sapiens (human)
extracellular exosomeNeprilysinHomo sapiens (human)
presynapseNeprilysinHomo sapiens (human)
plasma membraneNeprilysinHomo sapiens (human)
Golgi membraneEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
transport vesicle membraneEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
plasma membraneEEF1AKMT4-ECE2 readthrough transcript proteinHomo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
membraneType-1 angiotensin II receptorHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
lysosomal membraneEndothelin-converting enzyme 1Homo sapiens (human)
endosomeEndothelin-converting enzyme 1Homo sapiens (human)
plasma membraneEndothelin-converting enzyme 1Homo sapiens (human)
external side of plasma membraneEndothelin-converting enzyme 1Homo sapiens (human)
endosome membraneEndothelin-converting enzyme 1Homo sapiens (human)
membraneEndothelin-converting enzyme 1Homo sapiens (human)
vesicleEndothelin-converting enzyme 1Homo sapiens (human)
Weibel-Palade bodyEndothelin-converting enzyme 1Homo sapiens (human)
perinuclear region of cytoplasmEndothelin-converting enzyme 1Homo sapiens (human)
extracellular exosomeEndothelin-converting enzyme 1Homo sapiens (human)
plasma membraneEndothelin-converting enzyme 1Homo sapiens (human)
plasma membraneThiamine transporter 1Homo sapiens (human)
membraneThiamine transporter 1Homo sapiens (human)
plasma membraneThiamine transporter 1Homo sapiens (human)
cytoplasmNeprilysinHomo sapiens (human)
early endosomeNeprilysinHomo sapiens (human)
trans-Golgi networkNeprilysinHomo sapiens (human)
plasma membraneNeprilysinHomo sapiens (human)
brush borderNeprilysinHomo sapiens (human)
focal adhesionNeprilysinHomo sapiens (human)
synaptic vesicleNeprilysinHomo sapiens (human)
cell surfaceNeprilysinHomo sapiens (human)
membraneNeprilysinHomo sapiens (human)
axonNeprilysinHomo sapiens (human)
dendriteNeprilysinHomo sapiens (human)
secretory granule membraneNeprilysinHomo sapiens (human)
cytoplasmic vesicleNeprilysinHomo sapiens (human)
neuronal cell bodyNeprilysinHomo sapiens (human)
neuron projection terminusNeprilysinHomo sapiens (human)
membrane raftNeprilysinHomo sapiens (human)
synapseNeprilysinHomo sapiens (human)
extracellular exosomeNeprilysinHomo sapiens (human)
presynapseNeprilysinHomo sapiens (human)
plasma membraneNeprilysinHomo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAminopeptidase NHomo sapiens (human)
lysosomal membraneAminopeptidase NHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentAminopeptidase NHomo sapiens (human)
plasma membraneAminopeptidase NHomo sapiens (human)
external side of plasma membraneAminopeptidase NHomo sapiens (human)
secretory granule membraneAminopeptidase NHomo sapiens (human)
extracellular exosomeAminopeptidase NHomo sapiens (human)
cytoplasmAminopeptidase NHomo sapiens (human)
plasma membraneAminopeptidase NHomo sapiens (human)
extracellular spaceAminopeptidase NHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (136)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1205931Antibacterial activity against Escherichia coli BL21(DE3) cells harboring NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205931Antibacterial activity against Escherichia coli BL21(DE3) cells harboring NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID67194Inhibitory activity against human bronchiolar smooth muscle Endothelin-converting enzyme 11995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.
AID695876Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID147372The compound was tested in vitro for inhibition of Neutral endopeptidase by using Leu enkephalin as substrate1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.
AID132478The compound was tested for administrating the compound intravenously1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
A novel class of enkephalinase inhibitors containing a C-terminal sulfo group.
AID1205941Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205941Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID147226Inhibition of neutral endopeptidase (NEP)2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
AID38849Inhibition of angiotensin I converting enzyme in silico1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID1205925Inhibition of hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205925Inhibition of hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID67348In vitro inhibition of enkephalinase purified from rat kidney.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.
AID1205942Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2216 expressing VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205942Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2216 expressing VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID143520Inhibitory concentration was evaluated by Inhibiting 50% of Neutral endopeptidase enzyme (NEP) activity using 20 nM [3H]D-Ala2-Leu-enkephalin as substrate1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.
AID115608Hot-plate jump-latency activity in mouse 15 minutes after subcutaneous administration1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.
AID67355The compound was tested in vitro for its inhibitory activity against Enkephalinase enzyme1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
A novel class of enkephalinase inhibitors containing a C-terminal sulfo group.
AID1662235Inhibition of bacteria NMD-12020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.
AID147213Inhibitory activity against big ET-1 of Neutral endopeptidase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.
AID1205929Binding affinity to hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205929Binding affinity to hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1127282Inhibition of human NEP-mediated amyloid beta hydrolysis2014European journal of medicinal chemistry, May-22, Volume: 79Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis.
AID39770Inhibitory concentration was evaluated by Inhibiting 50% of Angiotensin I converting enzyme activity using 50 uM N-Cbz-Phe-His-Leu as substrate1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.
AID147371In vitro inhibition of rat neutral endopeptidase by using GAAP as substrate1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.
AID147367Tested in vitro for the inhibition against neutral endopeptidase (NEP) from rat kidney1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.
AID695877Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205937Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205937Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID110039Doubling of hotplate jump-latency activity in mouse after intra cerebro ventricular administration of the compound1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.
AID695851Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KBV1 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205934Antibacterial activity against Pseudomonas aeruginosa T2226 expressing IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205934Antibacterial activity against Pseudomonas aeruginosa T2226 expressing IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID114378Stretching activity in male CF-1 mice, after the intra peritoneal administration of acetic acid and subcutaneous administration of compound1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.
AID67345Inhibition of enkephalinase activity in membranes prepared from rabbit1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.
AID1205928Binding affinity to hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205928Binding affinity to hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205936Antibacterial activity against Klebsiella pneumoniae T2216 expressing VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205936Antibacterial activity against Klebsiella pneumoniae T2216 expressing VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID67359Binding affinity towards enkephalinase (metalloendopeptidase, E.C.3.4.24.11) of rat kidney1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and biological evaluation of phosphonamidate peptide inhibitors of enkephalinase and angiotensin-converting enzyme.
AID213088pKi value expresses binding affinity against thermolysin pKi = -logKi (where Ki is in mol/L)2002Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8
Development of new hydrogen-bond descriptors and their application to comparative molecular field analyses.
AID110042Doubling of hotplate jump-latency activity in mouse after subcutaneous administration of the compound1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.
AID1205933Antibacterial activity against Escherichia coli BL21(DE3) cells harboring IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205933Antibacterial activity against Escherichia coli BL21(DE3) cells harboring IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID228593In Vitro inhibition of recombinant human endothelin converting enzyme-12000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
AID38253Inhibition of Angiotensin I converting enzyme (ACE)2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
AID1205939Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205939Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID433786Inhibition of pig kidney NEP by fluorimetry2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID117550Tail-flick latency observed in CF-1 mice after the administration (3 mg/kg) followed by icv administration of DAEM ([D-Ala2,Met5]enkephalin)1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.
AID147352Evaluation of in vitro inhibitory activity against Neutral endopeptidase1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
AID1205927Binding affinity to hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205927Binding affinity to hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID213077Inhibitory concentration required to inhibit thermolysin1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.
AID67352Inhibition of enkephalinase activity in synaptic membranes prepared from rat striatum1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.
AID67205Inhibition of Endothelin-converting enzyme 1 (ECE)2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
AID235174Selectivity ratio of IC50 NEP/IC50 ECE2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
AID143636In vitro inhibition of rat neutral endopeptidase2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
AID147354In vitro inhibition of Neutral endopeptidase (NEP) enzyme1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.
AID1515581Inhibition of NEP (unknown origin) preincubated for 10 mins followed by fluorogenic substrate addition and measured after 20 mins by fluorescence assay
AID213070Inhibitory constant against thermolysin.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: validation of a high-resolution graphical tool for drug design.
AID132477The compound was tested for administrating the compound intracisternally1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
A novel class of enkephalinase inhibitors containing a C-terminal sulfo group.
AID1205935Antibacterial activity against Escherichia coli BL21(DE3) cells harboring VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205935Antibacterial activity against Escherichia coli BL21(DE3) cells harboring VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205940Ratio of imipenim MIC to imipenim MIC in presence of compound for Pseudomonas aeruginosa T2226 expressing IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205940Ratio of imipenim MIC to imipenim MIC in presence of compound for Pseudomonas aeruginosa T2226 expressing IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID147212Inhibitory activity against Leu-enkeph of Neutral endopeptidase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.
AID1205924Inhibition of hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205924Inhibition of hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID67338Inhibition of Endothelin-converting enzyme 1 activity at a concentration of 1 uM2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
AID147370The compound was tested in vitro for inhibition of Neutral endopeptidase by using ANF(atrial natriuretic factor) as substrate1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.
AID147391Inhibition of neutral endopeptidase1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.
AID1205938Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2301 expressing NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205938Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2301 expressing NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID37934In vitro inhibitory activity against angiotensin I converting enzyme (ACE) from rabbit lung1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
A novel class of enkephalinase inhibitors containing a C-terminal sulfo group.
AID1205932Antibacterial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205932Antibacterial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1515578Displacement of Europium-labeled angiotensin-2 from human AT1 receptor expressed in CHOK1 cell membranes after 120 mins by DELFIA
AID1205926Inhibition of hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205926Inhibition of hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1798102In Vitro Inhibition of NEP from Article 10.1021/jm0005454: \\Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).\\2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
AID1799789Enzymatic Assay from Article 10.1074/jbc.M110.120576: \\Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.\\2010The Journal of biological chemistry, Nov-05, Volume: 285, Issue:45
Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.
AID1799660Enzyme Inhibition Assay from Article 10.3109/14756369709035816: \\Novel selective thiol inhibitors of neutral endopeptidase containing heterocycles at P'2 position.\\1997Journal of enzyme inhibition, Jun, Volume: 12, Issue:2
Novel selective thiol inhibitors of neutral endopeptidase containing heterocycles at P'2 position.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID147228Tested for binding affinity against neutral endopeptidase (NEP)1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
AID67350Concentration for 50% inhibition of activity of rat kidney enkephalinase1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
1H NMR configurational correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of "enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition.
AID39767Inhibitory activity against angiotensin I converting enzyme (ACE)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID147220Tested for inhibition against neutral endopeptidase (NEP)1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
AID1607332Inhibition of human ACE using MCA-RPPGFSAFK-Dnp-OH as substrate by fluorescence based analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
AID1252360Inhibition of recombinant human Neprilysin using Suc-Ala-Ala-Phe-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorometry2015European journal of medicinal chemistry, Sep-18, Volume: 102Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.
AID67819Inhibitory activity against Endopeptidase2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1252361Inhibition of recombinant human Aminopeptidase N using L-Ala-beta-NA as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorometry2015European journal of medicinal chemistry, Sep-18, Volume: 102Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.
AID213071Tested for binding affinity against Thermolysin1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
AID9849Inhibitory activity against angiotensin-converting enzyme (ACE).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID213073Tested for binding against Thermolysin1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
AID1607331Inhibition of human NEP using MCA-RPPGFSAFK-Dnp-OH as substrate by fluorescence based analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
AID1224570Inhibition of human recombinant NEP using Suc-Ala-Ala-Phe-AMC as substrate after 30 mins by fluorimetry2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
AID1224598Drug level in rat plasma treated with 1-(2-(1-Ethoxycarbonyloxy-ethoxycarbonylmethyl)-carbamoyl)-3-phenyl-propyldisulfanylmethyl)-3-methylsulfanylpropyl-ammonium trifluoroacetate at 200 uM, po after 30 mins by LC/MS/MS analysis2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
AID1811Experimentally measured binding affinity data derived from PDB1989Biochemistry, Feb-21, Volume: 28, Issue:4
Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1989Biochemistry, Feb-21, Volume: 28, Issue:4
Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (636)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990150 (23.58)18.7374
1990's277 (43.55)18.2507
2000's109 (17.14)29.6817
2010's82 (12.89)24.3611
2020's18 (2.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.78 (24.57)
Research Supply Index6.57 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index45.20 (26.88)
Search Engine Supply Index1.94 (0.95)

This Compound (32.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials50 (7.52%)5.53%
Trials0 (0.00%)5.53%
Reviews28 (4.21%)6.00%
Reviews1 (12.50%)6.00%
Case Studies4 (0.60%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other583 (87.67%)84.16%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Racecadotril 100 mg FCT Versus Tiorfast® 100 mg Capsules, in Normal, Healthy, Non-Smoking Male and Female Subjects [NCT01302093]Phase 140 participants (Actual)Interventional2011-01-31Completed
Study of the Racecadotril Linearity After Single Administrations of 10, 30 and 60 mg of a New Racecadotril Formulation (Suspension) by Oral Route and Evaluation of the Comparative Bioavailability of This New Formulation Versus the Sachet Formulation (Gran [NCT01948011]Phase 153 participants (Actual)Interventional2013-09-30Completed
An Open-Label, Fasting, Crossover, Single-Dose Pharmacokinetic Study of Four Formulations of Racecadotril [NCT01476683]Phase 124 participants (Actual)Interventional2011-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]